Related Experiment Video

Updated: Mar 17, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer

Prabhat Singh Malik1, Deepali Jain, Lalit Kumar

  • 1Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, New Delhi, India.

Oncology
|July 28, 2016
PubMed

Insights

Epidermal growth factor receptor (EGFR) mutations guide lung cancer treatment. Understanding EGFR mutation prevalence in India versus other regions is crucial for effective, personalized lung adenocarcinoma therapy.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Advanced lung adenocarcinoma treatment has been revolutionized by epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
  • Therapeutic success hinges on identifying specific sensitizing EGFR mutations.
  • Ethnic variations in mutation prevalence necessitate regional epidemiological studies.

Purpose of the Study:

  • To review the epidemiology of EGFR mutations in India compared to other Asian countries and Western nations.
  • To examine the clinical experience with EGFR TKIs in diverse populations.
  • To propose strategies for optimizing TKI therapy in resource-limited settings.

Main Methods:

  • Literature review of epidemiological studies on EGFR mutations in lung adenocarcinoma.
  • Analysis of clinical data on EGFR TKI efficacy and outcomes.
  • Comparative analysis of mutation prevalence across different geographic regions.

Main Results:

  • Significant variations in EGFR mutation prevalence exist among different ethnic groups and geographic locations.
  • EGFR TKI efficacy is strongly correlated with the presence of specific sensitizing mutations.
  • Data highlights the need for region-specific treatment guidelines.

Conclusions:

  • Regional epidemiological data is essential for informed clinical decision-making in lung adenocarcinoma management.
  • Tailoring EGFR TKI therapy based on molecular profiling and regional prevalence is key.
  • Strategies for resource-limited settings are crucial for equitable access to targeted therapies.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
88.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
20.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63